Precision trial for biliary tract cancers
Part of Cancer, Digestive system clinical trials.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced bile duct or gallbladder cancer that has not been treated before with systemic therapy.
- You must have at least one measurable tumor on a CT scan.
- You must be in generally good health (able to care for yourself) and have adequate organ function.
- You cannot have other active cancers, uncontrolled infections, or serious heart problems.
- Women who can become pregnant must agree to use effective birth control; men must also use birth control with their partners.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (gemcitabine, nab-paclitaxel, lenvatinib, and tislelizumab) for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery and has not been treated before.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of radiation therapy (SBRT), two chemotherapy drugs (gemcitabine and cisplatin), and an immunotherapy drug (sintilimab) as a first-line treatment for advanced bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
This trial tests a combination of a cancer-fighting virus (H101), a targeted therapy (lenvatinib), and an immunotherapy (toripalimab) against a standard chemotherapy (FOLFOX) for people with advanced biliary tract cancer that has progressed after one prior treatment. The goal is to see if the new combination is more effective.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
Hear when a new Bile Duct Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.